Lung Cancer

Nivolumab versus docetaxel in patients with advanced squamous cell non-small cell lung cancer

Nivolumab versus docetaxel in patients with advanced squamous cell non-small cell lung cancer

By

Recent studies show that nivolumab was associated with increased overall survival rate when compared to docetaxel in patients with advanced squamous cell non-small cell lung cancer.

More incidental pulmonary nodules result from increased scanning

More incidental pulmonary nodules result from increased scanning

The number of incidental pulmonary nodules has increased though the number of lung cancer cases remained stable.

Medicare proposes to cover lung cancer screenings for at-risk patients

Medicare proposes to cover lung cancer screenings for at-risk patients

CMS announced it has drafted a reimbursement proposal to cover annual computed tomography (CT) scans for high-risk patients.

Experts weigh risks, benefits of lung cancer screening for seniors

Experts weigh risks, benefits of lung cancer screening for seniors

The government is evaluating the risks and benefits associated with low-dose CT scans and potential coverage changes for Medicaid patients.

Lung cancer screening cost-effective for Medicare beneficiaries

Lung cancer screening cost-effective for Medicare beneficiaries

Low-dose computed tomography screening is a low-cost strategy that can help the estimated 4.9 million Medicare patients that could meet criteria for lung cancer.

Lung cancer screening connected to smoking cessation

Lung cancer screening connected to smoking cessation

Further research into smoking cessation within screening programs may continue to decrease smoking rates.

FDA approves Zykadia for metastatic NSCLC

FDA approves Zykadia for metastatic NSCLC

The FDA has granted accelerated approval to Zykadia (ceritinib) in patients with metastatic ALK-positive non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

USPSTF: Screen high-risk adults for lung cancer

USPSTF: Screen high-risk adults for lung cancer

Screening urged for adults aged 55 to 80 years with 30 pack-year history who smoke or recently quit

Sign Up for Free e-newsletters